Previous Article | Next Article 
Journal of Virology, July 1999, p. 6024-6030, Vol. 73, No. 7
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Ebola Virus Can Be Effectively Neutralized by
Antibody Produced in Natural Human Infection
Toshiaki
Maruyama,1
Luis L.
Rodriguez,2,
Peter B.
Jahrling,3
Anthony
Sanchez,2
Ali S.
Khan,2
Stuart T.
Nichol,2
C. J.
Peters,2
Paul W. H. I.
Parren,1 and
Dennis R.
Burton1,*
Departments of Immunology and Molecular
Biology, The Scripps Research Institute, La Jolla, California
920371; Special Pathogens Branch,
Division of Viral and Rickettsial Diseases, National Center for
Infectious Diseases, Centers for Disease Control and Prevention,
Atlanta, Georgia 303332; and Pathology
Division, U.S. Army Medical Research Institute of Infectious
Diseases, Fort Detrick, Maryland 217023
Received 11 January 1999/Accepted 6 April 1999
The activity of antibodies against filoviruses is poorly understood
but has important consequences for vaccine design and passive
prophylaxis. To investigate this activity, a panel of recombinant human
monoclonal antibodies to Ebola virus antigens was isolated from phage
display libraries constructed from RNA from donors who recovered from
infection in the 1995 Ebola virus outbreak in Kikwit, Democratic
Republic of Congo. Antibodies reactive with nucleoprotein (NP),
envelope glycoprotein (GP), and secreted envelope glycoprotein (sGP)
were characterized by immunofluorescence and radioimmunoprecipitation
assays. Four antibodies reacting strongly with sGP and weakly with GP
and two antibodies reacting with NP were not neutralizing. An antibody
specific for GP neutralized Ebola virus to 50% at 0.4 µg/ml as the
recombinant Fab fragment and to 50% at 0.3 µg/ml (90% at 2.6 µg/ml) as the corresponding whole immunoglobulin G1 molecule. The
studies indicate that neutralizing antibodies are produced in infection
by Ebola virus although probably at a relatively low frequency. The
neutralizing antibody may be useful in vaccine design and as a
prophylactic agent against Ebola virus infection.
*
Corresponding author. Mailing address: Department of
Immunology, IMM2, The Scripps Research Institute, 10550 N. Torrey Pines Rd., La Jolla, CA 92037. Phone: (619) 784-9298. Fax: (619) 784-8360. E-mail: burton{at}scripps.edu.

Present address: USDA Agricultural Research Service, Plum Island
Animal Disease Center, Greenport, NY
11944.
Journal of Virology, July 1999, p. 6024-6030, Vol. 73, No. 7
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Calain, P., Fiore, N., Poncin, M., Hurst, S. A.
(2009). Research Ethics and International Epidemic Response: The Case of Ebola and Marburg Hemorrhagic Fevers. Public Health Ethics
2: 7-29
[Abstract]
[Full Text]
-
Smith, J. G., Cassany, A., Gerace, L., Ralston, R., Nemerow, G. R.
(2008). Neutralizing Antibody Blocks Adenovirus Infection by Arresting Microtubule-Dependent Cytoplasmic Transport. J. Virol.
82: 6492-6500
[Abstract]
[Full Text]
-
Hunt, A. R., Frederickson, S., Hinkel, C., Bowdish, K. S., Roehrig, J. T.
(2006). A humanized murine monoclonal antibody protects mice either before or after challenge with virulent Venezuelan equine encephalomyelitis virus. J. Gen. Virol.
87: 2467-2476
[Abstract]
[Full Text]
-
Grabenstein, J. D., Pittman, P. R., Greenwood, J. T., Engler, R. J.M.
(2006). Immunization to Protect the US Armed Forces: Heritage, Current Practice, and Prospects. Epidemiol Rev
28: 3-26
[Abstract]
[Full Text]
-
Alazard-Dany, N., Volchkova, V., Reynard, O., Carbonnelle, C., Dolnik, O., Ottmann, M., Khromykh, A., Volchkov, V. E.
(2006). Ebola virus glycoprotein GP is not cytotoxic when expressed constitutively at a moderate level.. J. Gen. Virol.
87: 1247-1257
[Abstract]
[Full Text]
-
Goncalvez, A. P., Men, R., Wernly, C., Purcell, R. H., Lai, C.-J.
(2004). Chimpanzee Fab Fragments and a Derived Humanized Immunoglobulin G1 Antibody That Efficiently Cross-Neutralize Dengue Type 1 and Type 2 Viruses. J. Virol.
78: 12910-12918
[Abstract]
[Full Text]
-
Moroncini, G., Kanu, N., Solforosi, L., Abalos, G., Telling, G. C., Head, M., Ironside, J., Brockes, J. P., Burton, D. R., Williamson, R. A.
(2004). Motif-grafted antibodies containing the replicative interface of cellular PrP are specific for PrPSc. Proc. Natl. Acad. Sci. USA
101: 10404-10409
[Abstract]
[Full Text]
-
Maruyama, T., Saito, I., Hayashi, Y., Kompfner, E., Fox, R. I., Burton, D. R., Ditzel, H. J.
(2004). Molecular Analysis of the Human Autoantibody Response to {alpha}-Fodrin in Sjogren's Syndrome Reveals Novel Apoptosis-Induced Specificity. Am. J. Pathol.
165: 53-61
[Abstract]
[Full Text]
-
Men, R., Yamashiro, T., Goncalvez, A. P., Wernly, C., Schofield, D. J., Emerson, S. U., Purcell, R. H., Lai, C.-J.
(2004). Identification of Chimpanzee Fab Fragments by Repertoire Cloning and Production of a Full-Length Humanized Immunoglobulin G1 Antibody That Is Highly Efficient for Neutralization of Dengue Type 4 Virus. J. Virol.
78: 4665-4674
[Abstract]
[Full Text]
-
Higo-Moriguchi, K., Akahori, Y., Iba, Y., Kurosawa, Y., Taniguchi, K.
(2004). Isolation of Human Monoclonal Antibodies That Neutralize Human Rotavirus. J. Virol.
78: 3325-3332
[Abstract]
[Full Text]
-
Sullivan, N., Yang, Z.-Y., Nabel, G. J.
(2003). Ebola Virus Pathogenesis: Implications for Vaccines and Therapies. J. Virol.
77: 9733-9737
[Full Text]
-
Nyamathi, A. M., Fahey, J. L., Sands, H., Casillas, A. M.
(2003). Ebola Virus: Immune Mechanisms of Protection and Vaccine Development. Biol Res Nurs
4: 276-281
[Abstract]
-
Niikura, M., Ikegami, T., Saijo, M., Kurata, T., Kurane, I., Morikawa, S.
(2003). Analysis of Linear B-Cell Epitopes of the Nucleoprotein of Ebola Virus That Distinguish Ebola Virus Subtypes. CVI
10: 83-87
[Abstract]
[Full Text]
-
Poignard, P., Moulard, M., Golez, E., Vivona, V., Franti, M., Venturini, S., Wang, M., Parren, P. W. H. I., Burton, D. R.
(2002). Heterogeneity of Envelope Molecules Expressed on Primary Human Immunodeficiency Virus Type 1 Particles as Probed by the Binding of Neutralizing and Nonneutralizing Antibodies. J. Virol.
77: 353-365
[Abstract]
[Full Text]
-
Parren, P. W. H. I., Geisbert, T. W., Maruyama, T., Jahrling, P. B., Burton, D. R.
(2002). Pre- and Postexposure Prophylaxis of Ebola Virus Infection in an Animal Model by Passive Transfer of a Neutralizing Human Antibody. J. Virol.
76: 6408-6412
[Abstract]
[Full Text]
-
Simmons, G., Wool-Lewis, R. J., Baribaud, F., Netter, R. C., Bates, P.
(2002). Ebola Virus Glycoproteins Induce Global Surface Protein Down-Modulation and Loss of Cell Adherence. J. Virol.
76: 2518-2528
[Abstract]
[Full Text]
-
Neumann, G., Feldmann, H., Watanabe, S., Lukashevich, I., Kawaoka, Y.
(2002). Reverse Genetics Demonstrates that Proteolytic Processing of the Ebola Virus Glycoprotein Is Not Essential for Replication in Cell Culture. J. Virol.
76: 406-410
[Abstract]
[Full Text]
-
Feldmann, H., Volchkov, V. E., Volchkova, V. A., Stroher, U., Klenk, H.-D.
(2001). Biosynthesis and role of filoviral glycoproteins. J. Gen. Virol.
82: 2839-2848
[Full Text]
-
Zwick, M. B., Labrijn, A. F., Wang, M., Spenlehauer, C., Saphire, E. O., Binley, J. M., Moore, J. P., Stiegler, G., Katinger, H., Burton, D. R., Parren, P. W. H. I.
(2001). Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41. J. Virol.
75: 10892-10905
[Abstract]
[Full Text]
-
Gupta, M., Mahanty, S., Bray, M., Ahmed, R., Rollin, P. E.
(2001). Passive Transfer of Antibodies Protects Immunocompetent and Immunodeficient Mice against Lethal Ebola Virus Infection without Complete Inhibition of Viral Replication. J. Virol.
75: 4649-4654
[Abstract]
[Full Text]
-
Williamson, R. A., Burgoon, M. P., Owens, G. P., Ghausi, O., Leclerc, E., Firme, L., Carlson, S., Corboy, J., Parren, P. W. H. I., Sanna, P. P., Gilden, D. H., Burton, D. R.
(2001). Anti-DNA antibodies are a major component of the intrathecal B cell response in multiple sclerosis. Proc. Natl. Acad. Sci. USA
98: 1793-1798
[Abstract]
[Full Text]